Skyhawk Therapeutics Massachusetts
07.08.2025 - 18:08:56Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease
https://twitter.com/Skyhawk_Tx
SKYHAWK MEDIA CONTACT:
Maura McCarthy maura@skyhawktx.com
Logo - https://mma.prnewswire.com/media/710814/Skyhawk_Therapeutics_Logo.jpg

